Why is remdesivir considered standard care despite survival benefit questions?

Question

Accepted Answer

Remdesivir Designated Standard Care Amidst Evolving Efficacy Data

Remdesivir has been established as the standard of care for hospitalised severe Covid-19 patients in the United States, a designation that persists despite ongoing questions regarding its impact on survival rates. This classification was largely cemented prior to its formal US Food and Drug Administration (FDA) approval, which occurred on October 23, following its availability under an emergency use authorisation (EUA) since May. The drug's role as a standard treatment has been influenced by early study results and its widespread use, even as broader data presents a more complex picture of its benefits.
Early Study Indicated Reduced Hospital Stays

A key factor contributing to remdesivir's early adoption and subsequent designation as standard care was a study conducted by the National Institutes of Health. This research indicated that the antiviral drug could reduce the duration of hospital stays for Covid-19 patients by approximately five days. Such a tangible benefit, even without a proven impact on mortality, provided a rationale for its use in managing hospital capacity and patient recovery timelines during the pandemic's initial surges.
WHO Trial Presented Conflicting Findings

In contrast to the NIH-led study, a global trial coordinated by the World Health Organisation (WHO) reported that remdesivir did not demonstrate a substantial effect on either the length of hospital stay or the survival chances of patients. This finding, which had not undergone external peer review at the time of reporting, presented a significant counterpoint to earlier conclusions. Gilead Sciences, the manufacturer of remdesivir, has raised concerns about potential bias in the WHO study, specifically noting that it was not a "blinded" trial, meaning participants and their caregivers were aware of the treatments administered.
Clinical Use Outpaced Definitive Survival Data

Despite the conflicting findings and the lack of definitive proof of improved survival, remdesivir has widely become the standard of care for those hospitalised with severe Covid-19. This status has been maintained even as evidence for its efficacy in moderately ill patients remains unproven, leading many physicians to express caution in its application for less severe cases. The drug's intravenous administration and its cost, approximately US$3,120 for a five-day treatment course, are significant considerations for its widespread deployment. Gilead has indicated plans to meet global demand for the drug by the end of October, underscoring its continued importance in treatment protocols.

Reading history

Hide →

This history is cleared when the page is closed.

Why is remdesivir considered standard care despite survival benefit questions?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends